Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...

A phase 3 trial of Intellia Therapeutics’ in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...

In late April 2026, Intellia Therapeutics completed a US$180.00 million follow-on offering of 16,744,187 common shares at US$10.75 each, shortly after reporting that its in vivo CRISPR therapy lonvo-z ...

CRISPR Therapeutics has announced promising early-phase results for its CAR T cell therapy, zugo-cel, in several autoimmune ...

Intellia’s in vivo CRISPR gene therapy for hereditary angioedema cut attack rates by 87% in a Phase III trial, prompting a rolling FDA submission. Novartis secured EU approval for the first oral ...

Gene editing is growing up. Ten years after Science magazine named CRISPR its 2015 “Breakthrough of the Year,” this revolutionary gene editing technology has become a workhorse of modern biology. In ...

JMIR Publications today featured two new stories in its News and Perspectives section, highlighting a shift toward proactive, ...

CRISPR Therapeutics' recent in vivo CTX310 data validates its technology, marking a fundamental shift and supporting a rating upgrade from Sell to Hold. CASGEVY sales are growing but remain ...

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...

-Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol- -Company announced ...

In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for ...